HK1124329A1 - Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors - Google Patents

Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

Info

Publication number
HK1124329A1
HK1124329A1 HK09103762.1A HK09103762A HK1124329A1 HK 1124329 A1 HK1124329 A1 HK 1124329A1 HK 09103762 A HK09103762 A HK 09103762A HK 1124329 A1 HK1124329 A1 HK 1124329A1
Authority
HK
Hong Kong
Prior art keywords
optionally substituted
benzothiophenes
indoles
seo
benzoselenophenes
Prior art date
Application number
HK09103762.1A
Other languages
English (en)
Inventor
Jason Hugh Chaplin
Gurmit Singh Gill
Damian Wojciech Grobelny
Bernard Luke Flynn
Gabriel Kremmidiotis
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Publication of HK1124329A1 publication Critical patent/HK1124329A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK09103762.1A 2006-02-03 2009-04-23 Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors HK1124329A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76533706P 2006-02-03 2006-02-03
PCT/AU2007/000101 WO2007087684A1 (fr) 2006-02-03 2007-02-02 Benzofurannes, benzothiophènes, benzosélénophènes et indoles substitués et leur emploi en tant qu'inhibiteurs de la polymérisation de la tubuline

Publications (1)

Publication Number Publication Date
HK1124329A1 true HK1124329A1 (en) 2009-07-10

Family

ID=38327089

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09103762.1A HK1124329A1 (en) 2006-02-03 2009-04-23 Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors

Country Status (12)

Country Link
US (5) US8198466B2 (fr)
EP (2) EP2460793A1 (fr)
JP (1) JP5315060B2 (fr)
AT (1) ATE555091T1 (fr)
AU (1) AU2007211840B2 (fr)
CA (1) CA2640678C (fr)
DK (1) DK1984333T3 (fr)
ES (1) ES2386299T3 (fr)
HK (1) HK1124329A1 (fr)
NZ (1) NZ570014A (fr)
PT (1) PT1984333E (fr)
WO (1) WO2007087684A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG150533A1 (en) 2003-11-20 2009-03-30 Janssen Pharmaceutica Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
NZ546990A (en) 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
AU2005259189B2 (en) 2004-06-30 2011-04-21 Janssen Pharmaceutica N.V. Phthalazine derivatives as PARP inhibitors
CA2568835C (fr) 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Derives de quinazolinone en tant qu'inhibiteurs de parp
MXPA06014541A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de quinazolindiona como inhibidores de la poli(adp-ribosa) polimerasa.
ES2386299T3 (es) 2006-02-03 2012-08-16 Bionomics Limited Benzofuranos, benzotiofenos, benzoselenofenos e indoles sustituidos y su uso como inhibidores de la polimerización de tubulina
CA2678248C (fr) 2007-03-08 2016-06-28 Janssen Pharmaceutica Nv Derives de quinolinone comme inhibiteurs de parp et de tank
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
US8168644B2 (en) 2008-03-27 2012-05-01 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
SI2271626T1 (sl) 2008-03-27 2015-03-31 Janssen Pharmaceutica, N.V. Tetrahidrofenantridinoni in tetrahidrociklopentakinolinoni, kot inhibitorji polimerizacije PARP in tubulina
US9006284B2 (en) * 2009-08-27 2015-04-14 Bionomics Limited Combination therapy for treating proliferative diseases
JP2013502440A (ja) * 2009-08-27 2013-01-24 バイオノミックス リミテッド 黄斑変性の治療
US20110130367A1 (en) * 2009-11-27 2011-06-02 Bionomics Limited Combination Therapy for Treating Proliferative Diseases
WO2011063469A1 (fr) * 2009-11-27 2011-06-03 Bionomics Limited Dosage de biomarqueur de tubuline
AU2009240878B2 (en) * 2009-11-27 2016-05-26 Bionomics Limited Combination Therapy for Treating Proliferative Diseases
EP2576514A1 (fr) 2010-06-04 2013-04-10 Exonhit Sa Isoquinoléines substituées et leur utilisation en tant qu'inhibiteurs de polymérisation des tubulines
US8674119B2 (en) 2010-07-16 2014-03-18 Bionomics Limited Chemical processes for the manufacture of substituted benzofurans
FR2962731B1 (fr) * 2010-07-19 2012-08-17 Sanofi Aventis Procede de preparation de derives d'amino-benzoyl-benzofurane
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
CN103221048A (zh) 2010-11-18 2013-07-24 卡斯纳莱拉创新药物私人有限公司 取代的4-(硒吩-2(或3)-基氨基)嘧啶化合物及其使用方法
AU2011340063B2 (en) * 2010-12-09 2016-03-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
US9039732B2 (en) 2011-07-11 2015-05-26 Covidien Lp Surgical forceps
EP2762472B1 (fr) 2011-09-28 2017-05-24 Industry-Academia Cooperation Group of Sejong University Composé aromatique condensé avec un sélénophène et son procédé de production
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
CN103058988B (zh) * 2012-12-31 2015-09-02 中国人民大学 苯并噻吩及其衍生物及其制备方法与应用
KR101584731B1 (ko) 2013-04-26 2016-01-12 한국생명공학연구원 신규 튜불린 중합 저해제 및 그 합성방법
WO2014175623A1 (fr) * 2013-04-26 2014-10-30 한국생명공학연구원 Nouvel inhibiteur de polymérisation de tubuline et procédé pour le synthétiser
WO2015149105A1 (fr) * 2014-04-04 2015-10-08 Bionomics Limited Méthode de traitement de la leucémie lymphocytaire chronique
US20170119727A1 (en) * 2014-05-30 2017-05-04 Bionomics Limited A therapeutic protocol for treating ovarian cancer
WO2016000012A1 (fr) * 2014-07-02 2016-01-07 Bionomics Limited Prédiction de réponse à une thérapie anticancéreuse
EP3164717B1 (fr) * 2014-07-02 2019-08-28 Bionomics Limited Biomarqueurs prédictifs
CN104860908B (zh) * 2015-04-28 2017-03-22 广东颐正达医药科技有限公司 一种合成bnc105的方法
AU2016275574B2 (en) * 2015-06-11 2019-07-11 Bionomics Limited Pharmaceutical combination and uses thereof
EP3386968A4 (fr) 2015-12-09 2019-09-25 The Board of Trustees of the University of Illinois Composés régulateurs à la baisse des récepteurs des strogènes sélectifs à base de benzothiophène
WO2017197055A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
WO2017197036A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
EP3455218A4 (fr) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
EA201990187A1 (ru) 2016-07-01 2019-07-31 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
CN107586284B (zh) * 2016-07-06 2021-03-26 中国药科大学 一种2-芳基苯并呋喃类衍生物在制备痛风药物中的用途
AU2017326751A1 (en) * 2016-09-16 2019-03-14 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
WO2018081168A2 (fr) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène
BR112019013814A2 (pt) 2017-01-06 2020-01-21 G1 Therapeutics Inc método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit.
AU2018217809A1 (en) 2017-02-10 2019-08-22 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
AU2018291026B2 (en) 2017-06-29 2022-09-01 G1 Therapeutics, Inc. Morphic forms of GIT38 and methods of manufacture thereof
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
JP2023509375A (ja) 2019-12-20 2023-03-08 シーフォー セラピューティクス， インコーポレイテッド Ｅｇｆｒの分解のためのイソインドリノン及びインダゾール化合物
JP2021120367A (ja) * 2020-01-30 2021-08-19 エイムドバイオ株式会社 ベンゾセレノフェン系化合物、これを含む薬学的組成物及び抗体−薬物複合体
AU2022328217A1 (en) 2021-08-12 2024-03-14 Kuleon Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
WO2024030968A1 (fr) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Composés pour moduler la protéine ret
WO2024097980A1 (fr) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Inhibiteurs de protéines ret-ldd
WO2024097989A1 (fr) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Agents de dégradation de protéine ret-ldd

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE198601T1 (de) 1992-05-20 2001-01-15 Merck & Co Inc Ester derivate von 4-aza-steroiden
EP0641204B1 (fr) 1992-05-20 2000-08-16 Merck & Co. Inc. 17-ethers et thioethers de 4-aza-steroides
ZA936492B (en) 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
ES2159618T3 (es) * 1993-11-17 2001-10-16 Kyowa Hakko Kogyo Kk Derivados de propenona.
US5728724A (en) * 1995-08-17 1998-03-17 Eli Lilly And Company Benzothiophene compounds
US5886025A (en) 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
CA2260499A1 (fr) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Compositions pharmaceutiques pour le traitement de dommages ischemiques au cerveau
AU3127900A (en) 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
AU776511B2 (en) 1999-02-18 2004-09-09 Baylor University Compositions and methods for use in targeting vascular destruction
CA2383988A1 (fr) 1999-09-17 2001-03-22 Baylor University Agents de polymerisation antimitotiques et antitubulines contenant de l'indole et apparentes a la combretastatine
WO2004099139A1 (fr) * 2000-09-15 2004-11-18 Baylor University Composes contenant de l'indole a activite anti-tubuline et de ciblage vasculaire
JP2003512326A (ja) 1999-10-18 2003-04-02 ユニヴァーシティ オブ コネチカット カンナビノイド相似インドール誘導体
AU2001239725A1 (en) 2000-01-13 2001-07-24 Tularik, Inc. Antibacterial agents
US7091240B2 (en) 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
JP2004505888A (ja) 2000-03-10 2004-02-26 ベイラー・ユニバーシテイ チューブリン結合リガンドおよび対応するプロドラッグ構造
DE10017947A1 (de) 2000-04-11 2001-10-25 Merck Patent Gmbh Verfahren zur Herstellung benzo-annelierter Heterocyclen
WO2002000651A2 (fr) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Inhibiteurs du facteur xa
FR2813308B1 (fr) 2000-08-23 2005-07-01 Sanofi Synthelabo Aminoalkoxybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation ainsi que les compositions les contenant
KR20030070054A (ko) 2000-12-05 2003-08-27 에프. 호프만-라 로슈 아게 벤조푸란 및 벤조티오펜 유도체
AUPR283801A0 (en) * 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
GB0106586D0 (en) 2001-03-16 2001-05-09 Smithkline Beecham Plc Novel compounds
ATE527247T1 (de) 2001-07-05 2011-10-15 Takeda Pharmaceutical Benzokondensierte 5gliedrige heterocyclische verbindungen, verfahren zu deren herstellung und deren verwendung
US7528165B2 (en) * 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
TWI317634B (en) 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
EP1400244A1 (fr) 2002-09-17 2004-03-24 Warner-Lambert Company LLC Nouveaux quinazolinones spirocondensés et leur utilisation comme inhibiteurs de la phosphodiesterase
EP1622886A2 (fr) 2003-04-30 2006-02-08 The Institutes for Pharmaceutical Discovery, LLC Acides amino-carboxyliques substitues comme inhibiteurs de proteine tyrosine-phosphatase-1b
US20050245489A1 (en) 2004-05-03 2005-11-03 Pinney Kevin G Chromene-containing compounds with anti-tubulin and vascular targeting activity
US7456214B2 (en) 2004-05-03 2008-11-25 Baylor University Chromene-containing compounds with anti-tubulin and vascular targeting activity
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
CA2597447C (fr) 2005-02-14 2014-03-25 Bionomics Limited Nouveaux inhibiteurs de polymerisation de la tubuline
ES2386299T3 (es) 2006-02-03 2012-08-16 Bionomics Limited Benzofuranos, benzotiofenos, benzoselenofenos e indoles sustituidos y su uso como inhibidores de la polimerización de tubulina

Also Published As

Publication number Publication date
NZ570014A (en) 2011-04-29
US20170020840A1 (en) 2017-01-26
AU2007211840B2 (en) 2012-03-01
US9346842B2 (en) 2016-05-24
US20130053351A1 (en) 2013-02-28
EP1984333A1 (fr) 2008-10-29
PT1984333E (pt) 2012-07-16
US8198466B2 (en) 2012-06-12
EP2460793A1 (fr) 2012-06-06
US8680135B2 (en) 2014-03-25
CA2640678A1 (fr) 2007-08-09
EP1984333B1 (fr) 2012-04-25
CA2640678C (fr) 2015-03-31
WO2007087684A1 (fr) 2007-08-09
US10213409B2 (en) 2019-02-26
US8716335B2 (en) 2014-05-06
JP5315060B2 (ja) 2013-10-16
US20100004208A1 (en) 2010-01-07
ATE555091T1 (de) 2012-05-15
US20140171642A1 (en) 2014-06-19
ES2386299T3 (es) 2012-08-16
JP2009531281A (ja) 2009-09-03
EP1984333A4 (fr) 2010-05-19
DK1984333T3 (da) 2012-07-23
US20120214770A1 (en) 2012-08-23
AU2007211840A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
HK1124329A1 (en) Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
ATE520656T1 (de) Verfahren zur herstellung von 2-oxo-1- pyrrolidinderivaten
TW200716525A (en) Process for preparation of sulfamide derivatives
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
WO2005044976A3 (fr) Composes oligomeres utilises pour la modulation de genes
WO2003053997A3 (fr) Methodes permettant d'augmenter l'erythropoietine endogene (epo)
WO2004098494A3 (fr) Composés, compositions et procédés
IL180518A0 (en) Novel carbamylated epo and method for its production
WO2006034093A3 (fr) Inhibiteurs de bace
MXPA06000123A (es) Suspension aislante de apoyo central de resorte rapido de plastico y metodo para fabricar y ensamblar el mismo.
WO2007011760A3 (fr) Inhibiteurs de la kinesine mitotique
PT1667964E (pt) Ácidos 4-((fenoxialquil)tio)-fenoxiacéticos e análogos
WO2007011759A3 (fr) Inhibiteurs de la kinesine mitotique
NO20062062L (no) Procsesser for preparering av forskjellige former for (S)-(+)-clopidogrel bisulfat
ATE486071T1 (de) Azabicycloä3.1.0ühexan-derivate als modulatoren des dopamin-d3-rezeptors
DE602005005298D1 (de) 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-chinazolin-2-on-derivate und die jeweiligen 1h-benzo(1,2,6)thiadiazin-2,2-dioxid und 1,4-dihydro-benzo(d)(1,3)oxazin-2-on-derivate als modulatoren des 5-hydroxytryptamin-rezeptors (5-ht) zur behandlung von erk
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
WO2004110990A3 (fr) Inhibiteurs de p38 et leurs methodes d'utilisation
CR8009A (es) Compuestos benzo[1,2,5] tiadiazoles
WO2005014536A3 (fr) Derives de podophyllotoxine
GB0423405D0 (en) Organic compounds
IL138688A0 (en) Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
WO2005034879A3 (fr) Traitement de maladies impliquant la surexpression de la kinase erbb2
EP2243766A3 (fr) Acides et analogues 4-(phénoxyalkyl)thio)-phénoxyacétique
MX2007016120A (es) Induccion de vasodilatacion de vasos sanguineos perifericos.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170202